An online version of a pioneering therapy aimed at reducing the lingering symptoms of depression can offer additional benefits for patients receiving care, according to a new U of T Scarborough study.
When added to regular depression care, the online version of Mindfulness-based Cognitive Therapy (MBCT) can help treat depression symptoms and help prevent its return, says U of T Scarborough Professor Zindel Segal, a clinical psychologist and lead author of the study.
“Treatments work well for many suffering from depression, but there remains a considerable group who continue to struggle with lingering symptoms such as sleep, energy or worry,” he says.
Clinical data shows that in the absence of treatment, these patients face a significantly higher risk of becoming fully depressed again, notes Segal.
“Patients with these residual symptoms face a gap in care since they are not depressed enough to warrant re-treatment, but receive few resources for managing the symptom burden they still carry.”
The digital version of MBCT, called Mindful Mood Balance (MMB), is an online adaptation of the effective treatment developed by Segal and his colleagues. It combines the practice of mindfulness meditation with the tools of cognitive therapy to teach patients adaptive ways of regulating their emotions. The practice of mindfulness meditation helps patients observe rather than act automatically to any thought, feeling or sensation that comes to mind, setting them up for being able to choose how best to respond, explains Segal.
“Our goal has always been for people to develop skills that they could continue to rely on once treatment had ended,” he says.
While research indicates that MBCT is as effective as antidepressant medication in preventing relapse, access remains limited and nearly impossible for those living outside large cities.
“What drove us to develop MMB is to improve access to this treatment. The online version uses the same content as the in-person sessions, except people can now avoid the barriers of cost, travel or wait times, and they can get the care they need efficiently and conveniently,” he says.
Segal, along with colleagues Arne Beck (Kaiser Permanente Institute for Health Research) and Sona Dimidjian (University of Colorado Boulder), received a $2 million grant in 2015 from the National Institute for Health (NIH) in the U.S. to develop MMB. The program was tested in a randomized clinical trial of 460 patients in clinics at Kaiser Permanente Colorado, a large American HMO in Colorado.
The results of the study, published in JAMA Psychiatry, found that adding MMB to depression care offered by Kaiser led to greater reductions in depressive and anxious symptoms, higher rates of remission and higher levels of quality of life compared to patients receiving conventional depression care alone.
“An online version of MBCT, when added with usual care, could be a real game changer because it can be offered to a wider group of patients for little cost,” says Segal.
Segal admits that even with the positive results, there is work to be done. A common trade-off with online programs is that drop-out rates tend to be higher than in-person treatment. An important next step is looking at ways to cut down on the dropout rate.
“The higher rates of dropout are somewhat offset by fact that you can reach many more people with online treatment,” he says. “But, there’s still room for improvement and we will be looking at our user metrics and outcomes for ways to make MMB more engaging and durable.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Using talk therapy to improve student mental health (continued)on November 27, 2020 at 2:00 am
The pandemic has impacted student mental health, but virtual therapy options can help improve the student experience on campus.
- TherapySpot’s Digital Patient Care in Speech Therapy Using Teletherapyon November 26, 2020 at 1:02 pm
TherapySpot has embraced teletherapy taking its patient care service to the next level. Therapeutic exercises are given to patients via video-conferencing applications. The therapist can show the ...
- Not just for the super-rich: the Covid boom in online therapy means we’re all seeing shrinks nowon November 19, 2020 at 6:04 am
Once upon a time, if you got a therapist you were labelled peculiar. These days, you’re more likely to be labelled peculiar for not seeing one. The old woke was being open with friends about mental ...
- Here's what most people are talking to their online therapists about during this strange, stressful yearon November 13, 2020 at 7:45 am
Verywell Mind surveyed Americans who use online therapy to determine what issues they're talking to their therapists about during this stressful year, with interesting findings. Read more ...
- Online therapy just as effective as in-person therapy for many patientson November 12, 2020 at 7:14 am
There may be a surprisingly simple solution: online therapy. Examining 5,568 patients at BYU's Counseling and Psychological Services in the largest study of its kind to date, Pescatello and a team ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Small businesses are seeing the biggest shift in how we shop since the Great Depression. Here's how entrepreneurs can reach the morally minded, Instagram-oriented customer.on November 28, 2020 at 5:30 am
This holiday season, consumers are shopping differently, using their dollars to reflect their values and have a greater impact. Experts argue that just as one day in the year doesn't define a ...
- Biogen bets on depression drug in $1.5 billion deal with Sage Therapeuticson November 27, 2020 at 3:31 pm
Biogen Inc will take a $650 million stake in Sage Therapeutics and make an upfront payment of $875 million to jointly develop and sell treatments for depression and other neurological disorders, the ...
- Biogen makes risky bet on trial depression drugon November 27, 2020 at 2:58 pm
The $1.5 billion deal with Sage Therapeutics will try to salvage an oral treatment that had a disappointing clinical trial ...
- Sage Gets $3 Billion Endorsement of Its Depression Drugs From Biogenon November 27, 2020 at 12:25 pm
Shaken by a government advisory panel’s poor review of its experimental treatment for Alzheimer’s disease, Biogen announced a team-up Friday with Sage Therapeutics. Biogen has committed up to $3.1 ...
- Sage to Get $1.53 Billion From Biogen for Depression Drug Developmenton November 27, 2020 at 9:42 am
The companies will develop Sage’s zuranolone for major depressive disorder, postpartum depression and other psychiatric disorders.